Leukemia is a malignancy of the hematopoietic system, and as its pathogenesis has
become better understood, three generations of tyrosine kinase inhibitors (TKIs) have been …

Background First-line imatinib treatment can be successfully discontinued in patients with
chronic myeloid leukaemia after deep molecular response has been sustained for at least 2 …

This article provides an overview of the genes and cellular processes that have emerged
recently as new key factors in tumorigenesis. We review these in the context of three broad …

The frontline tyrosine kinase inhibitor (TKI) imatinib has revolutionized the treatment of
patients with chronic myeloid leukemia (CML). However, drug resistance is the major clinical …

The oncogenic fusion protein BCR-ABL is the driving force of leukemogenesis in chronic
myeloid leukemia (CML). Despite the great advance in CML treatment through the …

The binding characteristics of calf thymus DNA (ct-DNA) with dasatinib (DSTN), a tyrosine
kinase inhibitor was assessed through multi-spectroscopic methodologies and viscosity …

Reactivation of hepatitis B virus (HBV) following immunosuppressive therapy or
hematopoietic stem cell transplantation is a potentially fatal complication that may occur …

Abstract The Brain-Expressed X-linked (BEX) family proteins are comprised of five human
proteins including BEX1, BEX2, BEX3, BEX4 and BEX5. BEX family proteins are expressed …

Despite the extensive work on pathological mechanisms and some recent advances in the
treatment of different hematological malignancies, leukemia continues to present a …

Simple Summary 2-Hydroxypropyl-β-cyclodextrin (HP-β-CyD) is a cyclic oligosaccharide
widely used as an excipient in pharmaceutical preparations, in addition to also being used …